Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy
CRANFORD, N.J., October 16, 2025 – Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has finalized an exclusive agreement with EVERSANA®, a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology’s FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy.
Under the Master Service Agreement, EVERSANA will serve as Citius Oncology’s exclusive commercialization partner, providing an integrated suite of pre- and post-launch operations services. These services include medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. As launch preparations advance, additional commercialization services are expected to be integrated.
This agreement marks an expansion of EVERSANA’s vital role in advancing Citius Oncology’s pre-commercial strategy, building on the foundational work already completed in preparation for the U.S. launch of LYMPHIR.
“Finalizing our exclusive agreement with EVERSANA is a transformative milestone as we prepare and plan to bring LYMPHIR to market in Q4 2025,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. “As a lean and strategically focused organization, this agreement allows us to significantly extend our commercial capabilities by leveraging EVERSANA's best-in-class infrastructure and deep expertise in oncology commercialization. EVERSANA's demonstrated ability to execute across the product lifecycle enhances our ability to scale efficiently, ensure timely market access for LYMPHIR, and support a high-quality launch aligned with investor expectations. We believe this collaboration strengthens our operational readiness, de-risks execution, and enhances our capacity to generate long-term value for shareholders.”
“We are committed to driving oncology commercialization excellence and look forward to continuing our work with Citius Oncology to bring LYMPHIR to market,” said Greg Skalicky, President, EVERSANA. “This agreement reflects our shared mission and vision to deliver innovative cancer treatments to patients who need them.”
LYMPHIR was approved by the U.S. Food and Drug Administration in August 2024 and is the only systemic treatment for CTCL that targets the IL-2 receptor on malignant T-cells and T-regs. Citius Oncology plans to commercially launch LYMPHIR in the United States in Q4 2025.
